Corneoplastic Unit, Queen Victoria Hospital, National Health Services Trust, East Grinstead, West Sussex, United Kingdom.
Corneoplastic Unit, Queen Victoria Hospital, National Health Services Trust, East Grinstead, West Sussex, United Kingdom.
Am J Ophthalmol. 2020 Jun;214:188-195. doi: 10.1016/j.ajo.2019.11.025. Epub 2019 Nov 23.
This article reports the outcomes of a 5-year series of individually sutured platinum segment chains for upper eyelid loading.
Consecutive case series.
Platinum segments of 0.4 and 0.2 g were assembled to create the desired weight and were placed in a supratarsal location after levator aponeurosis recession. Primary outcome measures included lagophthalmos on blink, gentle and forced eyelid closure, upper eyelid margin-to-reflex distance (MRD1), corneal staining, static and dynamic validated scoring for facial palsy patients, and complications. Secondary outcome measures were visual acuity, occurrence of induced ptosis, need for further surgery, cosmesis, and quality of life evaluation.
During 2013-2018, a total of 122 upper eyelids of 117 patients received platinum segment chains (mean weight, 1.2 ± 0.2 g; range, 0.8-1.6 g) for lagophthalmos. Median follow-up was 17.4 months. All grades of lagophthalmos were reduced (P < 0.001), with mean reductions of 3.6, 2.5, and 1.5 mm on blink, gentle, and forced closures, respectively. Mean MRD1 was reduced by 1.4 mm (P < 0.001). Overall, 36 eyelids (29.5%) underwent revision surgery at 9.1 ± 9.2 months after implantation. Of those, 6 eyelids (5.0%) required 2 or more procedures. No platinum allergy occurred. The chain was graded as having no prominence in 77.5% of eyelids; the eyelids were graded as having a normal contour in 70.8% of cases.
Platinum segments are US Food and Drug Administration approved and provide benefits of platinum chains with the additional advantages of allowing postoperative adjustability, reduced health care costs, and less likelihood of inducing allergy than gold. Platinum segments are an ideal first-line loading implant for lagophthalmos.
本文报告了 5 年来使用单独缝合铂金段链进行上睑负重的结果。
连续病例系列。
将 0.4 和 0.2 g 的铂金段组装成所需的重量,并在提上睑肌切开后放置在跗骨上方位置。主要结局指标包括眨眼时的睑裂闭合不全、轻闭眼和强闭眼时的睑裂闭合不全、上睑缘至反射距离(MRD1)、角膜染色、面瘫患者的静态和动态验证评分以及并发症。次要结局指标包括视力、是否出现诱导性上睑下垂、是否需要进一步手术、美容效果和生活质量评估。
在 2013 年至 2018 年期间,共有 117 例患者的 122 只上睑接受了铂金段链(平均重量为 1.2 ± 0.2 g;范围为 0.8-1.6 g)治疗睑裂闭合不全。中位随访时间为 17.4 个月。所有程度的睑裂闭合不全均得到改善(P < 0.001),眨眼、轻闭眼和强闭眼时的平均减少量分别为 3.6、2.5 和 1.5 mm。平均 MRD1 减少 1.4 mm(P < 0.001)。总体而言,36 只眼睑(29.5%)在植入后 9.1 ± 9.2 个月进行了修复手术。其中,6 只眼睑(5.0%)需要 2 次或更多次手术。没有发生铂金过敏。77.5%的眼睑段被评为无明显突出,70.8%的病例眼睑被评为正常轮廓。
铂金段已获得美国食品和药物管理局的批准,具有铂金链的优点,并且具有术后可调节性、降低医疗成本和减少过敏发生的可能性等额外优势,优于黄金。铂金段是治疗睑裂闭合不全的理想一线负重植入物。